




ANKTIVA® is indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

The unique action of ANKTIVA activates the body's natural immune system by proliferating natural killer cells, killer T Cells and memory T Cells to drive durable T Cell memory and durable responses.




Prolonged Duration of Response

Range of Duration of Response

0.0 to 47+ Months^{1,2}

and Ongoing


Represents the Upper Limit of the Range of Duration



Activating the innate and adaptive immune system without activation of immunosuppressive T Regs

ANKTIVA MOA Harnessing Nature's Immune System

ANKTIVA synergizes with BCG activating innate (NK) and adaptive (T Cell) immune memory – to overcome T Cell immune evasion^{1,3}



Open your camera and point your smart device at the QR code to access Anktiva.com

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. **WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy.** Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy. **DOSAGE AND ADMINISTRATION: For Intravesical Use Only.** Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. **USE IN SPECIFIC POPULATIONS: Pregnancy:** May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. **ADVERSE REACTIONS:** The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.Anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact ImmunityBio at 1-877-ANKTIVA (1-877-265-8482).

1. ANKTIVA Prescribing Information. ImmunityBio, Inc.; 2024.
2. Based on 48 patients that achieved a complete response at any time; reflects period from the time complete response was achieved. ANKTIVA Prescribing Information, Table 3. ImmunityBio, Inc.; 2024.
3. Han KP, et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. 2011 Dec; 56(3):804-10. doi: 10.1016/j.cyto.2011.09.028.